The DOI matches its Crossref record; 216 of the 224 references it cites were found in a registry or an index; 2 of the 182 sources its claims cite were checked for support.
Molecular pathology of age-related macular degeneration
Open accessAbstract
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the world. Although the etiology and pathogenesis of AMD remain largely unclear, a complex interaction of genetic and environmental factors is thought to exist. AMD pathology is characterized by degeneration involving the retinal photoreceptors, retinal pigment epithelium, and Bruch’s membrane, as well as, in some cases, alterations in choroidal capillaries. Recent research on the genetic and molecular underpinnings of AMD brings to light several basic molecular pathways and pathophysiological processes that might mediate AMD risk, progression, and/or response to therapy. This review summarizes, in detail, the molecular pathological findings in both humans and animal models, including genetic variations in CFH, CX3CR1, and ARMS2/HtrA1, as well as the role of numerous molecules implicated in inflammation, apoptosis, cholesterol trafficking, angiogenesis, and oxidative stress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
143 Not checked yet · 38 No basis given · 31 Own interpretation · 2 Partly supported · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CX3CR1 positive cells in drusen and near CNV membranes are microglial cells in human AMD eyes (Combadiere et al., 2007).”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
What the sources say
- Partly supportedcites Combadiere et al., 2007 sourceExperimental — accuracy not yet measured
The CX3CR1 expression in AMD section identifies CX3CR1-positive cells as CD18-positive microglial cells and reports them in close contact with CNV (Figure 1C–E, G). But Figure 1F describes the CX3CR1 material in drusen as acellular deposits, not microglial cells in drusen. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“We recently found no relationship between risk-conferring CFH variant and C. pneumoniae in 148 advanced AMD patients and 162 control subjects with the infection”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Shen et al., 2008
plainn = 148- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“although there is a positive association between AMD and C. pneumoniae infection (20% vs. 10% positive C. pneumoniae DNA detected in the blood of AMD patients compared with the controls) (Shen et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Shen et al., 2008
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This previous study showed that CX3CR1 transcript and protein in the AMD maculae were undetectable or expressed at much lower levels than their SNP-type counterparts in the normal eyes.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Chan et al., 2005
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“we found lowered CX3CR1 expression in the macula compared with the perimacular retina of AMD eyes bearing T280M.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Chan et al., 2005
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In normal eyes, macular cells from an individual bearing “at risk” allele T/M280 exhibited lower CX3CR1 transcript expression than an individual bearing “wild type or major” allele T280T.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Chan et al., 2005
plaincorrelationalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In contrast, similar levels of CX3CR1 expression were detected in macular and perimacular regions of the normal subjects”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Chan et al., 2005
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our data, including a population-based study (Wang et al., 2008), and data by Jakobsdottir and colleagues (Jakobsdottir et al., 2005) have both shown that the frequency of the ARMS2 risk allele is higher in patients with advanced AMD than in those with early or intermediate AMD.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Similar to findings by Feher and colleagues (Feher et al., 2006), we have also found a drastic decrease in normal mitochondria in the photoreceptors and RPE cells of the AMD eyes as compared to that of the normal age-control eyes (Fig. 5).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
- Not checked yetcites Feher et al., 2006 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“We have also found the association between ApoE112R (E4) and a decreased risk of AMD development, and the underlying mechanisms might involve differential regulation of both CCL2 and VEGF by the ApoE isoforms (Bojanowski et al., 2006).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.5. Apolipoprotein E (ApoE)
What the sources say
- Not checked yetcites Bojanowski et al., 2006 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 58
- Probably not a substantial claim. 17
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Funduscopic examination and vasculature, however, appears normal in the cfh−/− mice.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.3. Cfh−/− murine model
What the sources say
- Partly supportedcites Coffey et al., 2007 sourceExperimental — accuracy not yet measured
The Results (page not available) report no vascular leakage on fluorescein angiography in either group, supporting a limited claim about the vasculature. The paper says fundus photographs were taken but does not report a normal funduscopic examination; its retinal imaging instead found significantly more autofluorescent foci in cfh−/− mice. (LLM, conf=0.83)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
In the paper
“We have reported that the V249I (valine to isoleucine at amino acid 249) and T280M (threonine to methionine at amino acid 280) CX3CR1 SNPs confer increased risk of AMD (Tuo et al., 2004). The OR (CI) of these two SNPs were 1.86 (1.04–3.31) for V249I and 1.94 (1.02–3.69) for T280M.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Tuo et al., 2004 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“By examining four cohort studies, we have also confirmed this association with ORs of 2.17 and 2.97 for dry and wet AMD, respectively (Tuo et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
- Not checked yetcites Tuo et al., 2008 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Macrophage and microglial accumulation was also increased relative to wild-type in Ccl2−/−/Cx3cr1−/− mice, as well as in Cx3cr1−/− mice, though to a lesser degree (Ross et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
What the sources say
- Not checked yetcites Ross et al., 2008 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“We found that Ccl2−/−/Cx3cr1−/− mice exhibited, at an early age of 4–6 weeks, fundoscopically visible drusen-like lesions, as well as histological signs of AMD such as thickening of Bruch’s membrane, drusen, local RPE hypopigmentation and degeneration, and photoreceptor disorganization and atrophy, as well as CNV in some mice.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“AMD pathology is characterized by degeneration involving the retinal photoreceptors, retinal pigment epithelium, and Bruch’s membrane, as well as, in some cases, alterations in choroidal capillaries.”
§ Molecular pathology of age-related macular degeneration > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“analyses have revealed protective effects from antioxidants, nuts, fish, and omega-3 polysaccharide unsaturated fatty acids (AREDS, 2001; Cho et al., 2001; Seddon et al., 1994, 2001; Smith et al., 2000).”
§ Molecular pathology of age-related macular degeneration > 1. Introduction > 1.2. Risk factors for AMD
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Both fat intake and obesity have been linked to increased risk of AMD (Mares-Perlman et al., 1995; Seddon et al., 2003)”
§ Molecular pathology of age-related macular degeneration > 1. Introduction > 1.2. Risk factors for AMD
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Early AMD is characterized by thickening and loss of normal architecture within Bruch’s membrane, lipofuscin accumulation in the RPE, and drusen formation beneath the RPE in Bruch’s membrane”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.1. Early stage AMD
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A recent study of age-related changes demonstrates recruitment of leukocytes and activation of the complement cascade in mouse RPE and choroid (Chen et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD
What the sources say
- Not checked yetcites Chen et al., 2008 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recurrence risks in relatives indicate increased relative risks in siblings (2.95), first cousins (1.29), second cousins (1.13), and parents (5.66) of affected cases (Luo et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 1. Introduction > 1.2. Risk factors for AMD
What the sources say
- Not checked yetcites Luo et al., 2008 source
hedgedcorrelationaln = 4,764- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The larger the drusen, the greater the area they cover, and the larger the areas of hyperpigmentation and hypopigmentation of the RPE in the macula, the higher the risk of late age-related macular degeneration is (Klein et al., 2002).”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.1. Early stage AMD
What the sources say
- Not checked yetcites Klein et al., 2002 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Aging is associated with changes in the retina, including alterations in RPE cellular size and shape, thickening of Bruch’s membrane, thickening of the internal limiting membrane, and a decrease in retinal neuronal elements (Green, 1996).”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD
What the sources say
- Not checked yetcites Green, 1996
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“BlinL consist of vesicular material located in the inner collagenous zone of Bruch’s membrane and represent a specific marker for AMD (Curcio and Millican, 1999).”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.1. Early stage AMD
What the sources say
- Not checked yetcites Curcio and Millican, 1999
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“recent studies have generated significant interest in the inflammatory underpinnings of AMD pathogenesis (Klein et al., 2008b).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Klein et al., 2008b
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These SNPs lie in genes encoding complement factors, chemokines and chemokine receptors, and toll-like receptors.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Loss of RPE cells responsible for servicing the overlying photoreceptors leads to the gradual degeneration of nearby photoreceptors, resulting in thinning of the retina (Fig. 2) and a progressive visual impairment.”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.2. Late stage AMD
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“RAP refers to new vessel development extending outward into the subretinal space from the neurosensory retina, sometimes anastomosing with the choroid-derived vessels (Lafaut et al., 2000).”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.2. Late stage AMD
What the sources say
- Not checked yetcites Lafaut et al., 2000 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Classical neovascular AMD is mainly illustrated with CNV and subretinal neovascular fibrous tissue (Fig. 3).”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.2. Late stage AMD
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Choroidal neovascularization (CNV) is the defining characteristic of late stage ‘wet’ or neovascular AMD.”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.2. Late stage AMD
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“it has long been recognized that drusen are the hallmark lesions of AMD.”
§ Molecular pathology of age-related macular degeneration > 2. Pathology of AMD > 2.1. Early stage AMD
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“CFH inhibits the alternative pathway by promoting Factor I-mediated inactivation of C3b or by displacing Factor Bb from the C3bBb complex (Alsenz et al., 1985).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Alsenz et al., 1985 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Yu et al. also show no significant difference in their protein secretion, cofactor activity, or interaction with heparan, but a significant difference in binding to CRP (Yu et al., 2007).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Yu et al., 2007
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“CFH is encoded within the interval of chromosome 1q23–32, a region associated with AMD previously through linkage studies (Klein et al., 1998).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Klein et al., 1998 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“AMD patients have been found to possess increased serum anti-C. pneumoniae antibodies, and these antibodies have been linked to increased risk of AMD progression (Robman et al., 2005).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Robman et al., 2005 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a recent publication indicates that CFH binds to the denatured rather than native CRP, thus casting some doubt upon this link between CFH and CRP (Hakobyan et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Hakobyan et al., 2008 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“the L9H BF/E318D C2 and R32Q BF/intronic variants of C2 have been shown to be protective for AMD (odds ratio (OR) = 0.45 and 0.36, respectively) by Gold et al.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Gold et al., 2006 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the current data suggest a central role for innate immunity and inflammation in general and complement overactivation in particular for AMD pathogenesis.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In individuals homozygous for the non-risk phenotype (Y402Y/Y402Y), 34% of those treated with placebo progressed to advanced AMD, compared with 11% of those treated with antioxidants plus zinc, a reduction of approximately 68%. In contrast, in individuals homozygous for the risk-conferring phenotype (Y402H/Y402H), 44% of those treated with placebo group progressed to advanced AMD, compared with 39”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Klein et al., 2008a
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Variation near the FI gene on chromosome 4q25 is associated with risk of advanced AMD, although no obvious functional variation has been discovered (Fagerness et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Fagerness et al., 2008
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“C3F has in fact been associated with several diseases, including membranoproliferative glomerulonephritis type II (Montes et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
What the sources say
- Not checked yetcites Montes et al., 2008 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The interleukin-8 (IL8) A251T genetic polymorphism located in chromosome 4q13–21 is reported to be associated with AMD, with the homozygous AA genotype (A allele) as the “at risk” factor (Goverdhan et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Goverdhan et al., 2008 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“whose immunohistochemical analysis in humans showed that CX3CR1 was expressed on all retinal microglial cells, and these cells are the only cells in the retina that express CX3CR1.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Combadiere et al., 2007 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A study by Zareparsi et al reported that the D299G (aspartate to glycine at amino acid 299) TLR4 (encoded in chromosome 9q32–33) polymorphism leads to increased AMD risk (OR = 2.65) (Zareparsi et al., 2005).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Zareparsi et al., 2005 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“This finding of an AMD susceptibility locus on chromosome 10q26 has been replicated by other genome-wide linkage studies (Weeks et al., 2004) and supported by a genome-scan meta-analysis (Fisher et al., 2005).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Functionally, the D299G TLR4 variant has been linked to impaired LPS responsiveness in mice, which is reversible by TLR4 overexpression (Arbour et al., 2000).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
What the sources say
- Not checked yetcites Arbour et al., 2000 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the relationships of these SNPs with AMD are still preliminary or controversial to date and require additional studies in diverse and larger populations.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.3. Chemokines and chemokine receptors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have shown that rs11200638 in the promoter region is the most well-documented, statistically significant AMD-associated SNP with a high OR of 1.60–2.61 and 6.56–10.0 in heterozygous and homozygous individuals (Caucasians, Chinese and Japanese), respectively (Cameron et al., 2007; Deangelis et al., 2008; Dewan et al., 2006; Mori et al., 2007; Tam et al., 2008; Yang et al., 2006).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“First, studies have shown that human donor AMD eyes contain higher levels of protein adducts resulting from the oxidative modification of carbohydrates and lipids (Crabb et al., 2002; Howes et al., 2004) and higher levels of antioxidant enzymes (Decanini et al., 2007; Frank et al., 1999) compared with non-AMD eyes, which indicate that oxidative stress plays an important role in AMD.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Several lines of evidence indicate that mitochondria play a central role in aging and in the pathogenesis of AMD.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Fritsche et al. also showed that ARMS2 protein in the human retina localizes to the photoreceptor layer and that it demonstrates a minor dot-like staining in the ellipsoid region of the rod and cone inner segments, which fully co-localizes with a mitochondrial marker, anti-MTCO2, suggesting that ARMS2 is expressed in the mitochondria (Fritsche et al., 2008).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
- Not checked yetcites Fritsche et al., 2008 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Most importantly, since the A69S and InDel are in 100% LD and on the same haplotype, the effects are not independent to each other.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“VEGF plays a critical role in the pathogenesis of neovascular AMD, and recently, therapies targeting VEGF have shown promising results of significant improvement of central vision and reduction of CNV (Wylegala and Teper, 2007).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.6. VEGF
What the sources say
- Not checked yetcites Wylegala and Teper, 2007
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recently Kanda et al. reported that ARMS2 (T allele at rs10490924, A69S), rather than HtrA1, to be truly associated with AMD (Kanda et al., 2007).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.4. LOC387715/ARMS2 and HtrA1
What the sources say
- Not checked yetcites Kanda et al., 2007 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.6. VEGF
What the sources say
- Not checked yetcites Ferrara et al., 2003 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“One study has demonstrated that the ERCC6 C6530G SNP is modestly associated with AMD susceptibility, its interaction with a SNP (rs380390) in the CFH intron is highly associated with AMD (Tuo et al., 2006).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.7. ERCC6
What the sources say
- Not checked yetcites Tuo et al., 2006 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These conflicting data could result from differences of the ethnicities studied, study designs, and statistical analyses.”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.6. VEGF
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, the RPE cell is one of many systems that downregulate the immune response in the eye, and thus the pathway between RPE damage and ocular inflammation is likely a two way street whereby RPE damage potentiates inflammation, which further worsens RPE degeneration.”
§ Molecular pathology of age-related macular degeneration > 4. Involvement of inflammatory cells
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Neovascular AMD was found to be associated with the rs2010963 (G634C) VEGF-A SNP in a case-control cohort, and in a family cohort with two intronic VEGF-A SNPs (rs833070 and rs3025030) (Haines et al., 2006).”
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.6. VEGF
What the sources say
- Not checked yetcites Haines et al., 2006 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The main drawback of using mice to study AMD is that the mouse retina has no macula.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.1. Introduction
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Moreover, Cx3cr1−/− mice exhibited increased microglial accumulation after laser-injury, as well as worsened laser-induced CNV and retinal degeneration.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
What the sources say
- Not checked yetcites Combadiere et al., 2007 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cx3cr1−/− mice demonstrated retinal degeneration and drusen-like deposits, which contained bloated accumulated microglia capable of phagocytosing outer segments of photoreceptor cells in 18 months and older mice.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
What the sources say
- Not checked yetcites Combadiere et al., 2007 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Microglia are the resident immune cells in the retina required for neuronal homeostasis and innate immune defense (Langmann, 2007).”
§ Molecular pathology of age-related macular degeneration > 4. Involvement of inflammatory cells > 4.2. Microglia
What the sources say
- Not checked yetcites Langmann, 2007 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Animal models based upon Ccl2 and Cx3cr1 knockout have lent strength to this hypothesis and provided some insights into the potential inflammatory mechanisms underlying AMD pathogenesis.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These findings are consistent with findings in drusen of humans with AMD (Hageman et al., 2005), as well as the critical role in AMD of complement overactivity, which has been discussed above.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
What the sources say
- Not checked yetcites Hageman et al., 2005 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As discussed above, CFH polymorphisms are associated with susceptibility to AMD in more than half of affected individuals.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.3. Cfh−/− murine model
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings highlight that the Ccl2−/−/Cx3cr1−/− murine model of AMD is a robust one with several immunological features also documented in human AMD and supported by studies in other in vivo models of AMD.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.2. Chemokine model
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Moreover, CNV in aged ApoE4 mice on the HF-CR diet contained amyloid β deposits, as well as VEGF and other factors also seen in human AMD and CNV.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.4. ApoE-based murine model
What the sources say
- Not checked yetcites Malek et al., 2005 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These mice also demonstrated increased autofluorescence, accumulation of C3, and disorganization of photoreceptor outer segments in the retina, as well as thinning of Bruch’s membrane and increased RPE organelles.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.3. Cfh−/− murine model
What the sources say
- Not checked yetcites Coffey et al., 2007 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As discussed above, prior studies have suggested a probable association between ApoE polymorphisms and AMD.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.4. ApoE-based murine model
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“Aged ApoE4 mice on this diet exhibited several features of human AMD, including drusen, thickening of Bruch’s membrane, geographic RPE atrophy, and CNV.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.4. ApoE-based murine model
What the sources say
- Not checked yetcites Malek et al., 2005 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Moreover, the eyes of ApoE2 transgenic mice also expressed higher levels of the proangiogenic factor VEGF but lower levels of anti-angiogenic factor pigment epithelium derived factor (PEDF).”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.4. ApoE-based murine model
What the sources say
- Not checked yetcites Lee et al., 2007
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Abcr−/− mice demonstrate decreased dark adaptation, increased all-trans-retinaldehyde after light exposure, increased phosphatidylethanolamine (PE) in outer segments, accumulation of N-retinylidene-phosphatidylethanolamine, the conjugate of all-trans retinaldehyde and PE in photoreceptors, and deposition of A2E fluorophore, a major component of lipofuscin, in the RPE (Weng et al., 1999).”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.5. Abcr−/− murine model
What the sources say
- Not checked yetcites Weng et al., 1999 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most importantly, the ApoE-based murine model of AMD highlights the potential role for cholesterol metabolism in AMD pathogenesis and further emphasized the need to clarify the role of ApoE variants in human AMD.”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.4. ApoE-based murine model
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“While several risk factors, including age, race, smoking, and diet have been linked to AMD, the etiology and pathogenesis of the disease remain largely unclear.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Though AMD research has made great advances in recent years, our understanding of its pathogenesis remains largely incomplete.”
§ Molecular pathology of age-related macular degeneration > 7. Future direction
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“CFH polymorphisms have been linked to a pro-inflammatory state, including increased CRP and decreased complement inhibitory effect.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“VEGF is a key angiogenic factor in the development of CNV in late stage AMD, and recent studies suggest that polymorphisms in the VEGF gene might contribute to risk of AMD and to efficacy of anti-VEGF therapy.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The role of oxidative stress is further strengthened by epidemiological studies demonstrating increased risk with smoking, a potent oxidizing stress, and decreased risk with diets rich in antioxidants such as lutein/zeaxanthin.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Treatment options for the condition are similarly limited.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Pathology of AMD lesions classically demonstrates signs of persistent chronic inflammatory damage, including not only mild infiltration of macrophages and accumulation of microglia, but also presence of inflammatory components such as complement factors and pro-inflammatory cytokines/chemokines in the drusen and AMD lesions.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“AMD is a debilitating disease of the retina, which manifests clinically with loss of central vision and pathologically with the accumulation of drusen, RPE degeneration, photoreceptor atrophy, and in some cases, with CNV.”
§ Molecular pathology of age-related macular degeneration > 6. Summary
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Ultrastructural analysis revealed abnormal basal RPE with small irregular dense bodies in both abcr−/− and abcr+/− mice, but no drusen formation (Mata et al., 2001).”
§ Molecular pathology of age-related macular degeneration > 5. Animal models of AMD > 5.5. Abcr−/− murine model
What the sources say
- Not checked yetcites Mata et al., 2001
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Innovation in AMD pharmacotherapy depends largely on a thorough understanding of the molecular mechanisms underlying AMD pathogenesis.
“Innovation in AMD pharmacotherapy, in turn, depends largely upon a thorough understanding of the molecular mechanisms underlying AMD pathogenesis.”
The paper relies on this without support.
AMD is a multifactorial disease that primarily affects photoreceptors and RPE cells.
“AMD is a multifactorial disease that affects primarily the photoreceptors and RPE cells.”
The paper relies on this without support.
The mouse retina has no macula.
“The main drawback of using mice to study AMD is that the mouse retina has no macula.”
The paper relies on this without support.
Laser-induced CNV and CNV associated with age-related degenerative retinal changes arise through different mechanisms.
“These studies might be reconciled by the argument that laser-induced CNV, an acute injury, occurs by a different mechanism than CNV associated with age-related degenerative changes in the retina.”
The paper relies on this without support.
Many critical biological processes are context specific.
“Given the context specificity of many critical biological processes and the fact that most common diseases including AMD are thought to be the outcome of a complex interaction between many genetic loci and the environment, it follows that there are obvious advantages to studying gene expression in cells and tissues that represent the in vivo state.”
The paper relies on this without support.
Common diseases including AMD result from complex interactions between many genetic loci and the environment.
“Given the context specificity of many critical biological processes and the fact that most common diseases including AMD are thought to be the outcome of a complex interaction between many genetic loci and the environment, it follows that there are obvious advantages to studying gene expression in cells and tissues that represent the in vivo state.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although other susceptibility genes have been reported, these four SNPs have consistently been shown to have the strongest associations with the development and progression of AMD and have been postulated to influence response to therapy.2,3,12”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pioneering developments in AMD genetics research have identified numerous single nucleotide polymorphisms (SNPs) in multiple genes associated with the prevalence of the early and/or late stages of AMD.2,3”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“It has been hypothesized that overexpression of HTRA1 may alter the integrity of Bruch’s membrane and favor the development of CNV.2”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [2]
In the citing paper
“Loss of mitochondria is also reported in AMD retina (Ding et. al, 2009).”
From Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) (2010) · cites this paper as Ding et. al, 2009
In the citing paper
“AMD still has an unknown etiology, though oxidative stress to the retinal pigment epithelium (RPE) cells along with immune dysregulation are leading theories of AMD pathogenesis (Ding et al., 2009).”
From Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) (2010) · cites this paper as Ding et al., 2009
In the citing paper
“There is an age-related increase in thickness in Bruch’s membrane and the internal limiting membrane (Sarks, 1976; Ding et al., 2009).”
From Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) (2010) · cites this paper as Ding et al., 2009
In the citing paper
“The Ccl2−/−/Cx3cr1−/− mouse model demonstrates many AMD features: small drusenoid deposits, RPE and Bruch’s membrane degenerations, photoreceptor atrophy, CNV, and simulation of the immunologic and pathologic environments found in AMD patients (Herzlich et al., 2008; Ross et al., 2008; Ding et al., 2009).”
From Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) (2010) · cites this paper as Ding et al., 2009
In the citing paper
“The molecular pathology of dry AMD has demonstrated a role of oxidative stress, inflammation, and metabolic dysregulation”
From Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) (2010) · cites this paper as Ding et al. 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Molecular pathology of age-related macular degeneration > 3. Single nucleotide polymorphisms and molecular pathology of AMD > 3.2. Complement system
“Brantley et al. investigated 86 wet AMD patients to determine whether there is an association between CFH genotypes and response to treatment with intravitreal bevacizumab.”
§ Molecular pathology of age-related macular degeneration > References
“19. Brantley MA Jr Edelstein SL King JM Plotzke MR Apte RS Kymes SM Shiels A Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy Eye 2008”
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 2×
“VEGF It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
BackgroundThe chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534 · cited 3×
“A dual role for macrophages in AMD—Another plausible explanation for these seemingly contradictory findings is that macrophages comprise a heterogeneous group with a spectrum of phenotypes and activities (Mantovani et al., 2004).”
BackgroundResultInfluentialRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441406 · Cited by 2,969 · cited 1×
“…of the complement system generates a variety of pro-inflammatory responses, including the production of membrane-attack complexes (MAC) which lead to cell lysis, release of chemokines to mediate recruitment of inflammatory cells, and enhancement of capillary permeability (Walport, 2001a, b).”
BackgroundPrevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,783 · cited 2×
“Currently, in the United States alone, 1.75 million people are affected by AMD and 7 million people are at risk of developing AMD (Friedman et al., 2004).”
BackgroundInfluentialComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 4×
“These SNPs have been reported to be major genetic factors for developing AMD in Caucasians (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005; Tuo et al., 2006).”
BackgroundInfluentialComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 4×
“These SNPs have been reported to be major genetic factors for developing AMD in Caucasians (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005; Tuo et al., 2006).”
BackgroundInfluentialPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“…Inhibition Study in Ocular Neovascularization, Clinical Trial and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) (AREDS, 2001; Bressler et al., 2003; Gragoudas et al., 2004; Rosenfeld et al., 2006).”
Background
Research works printed but not linked: 3
- de Jong, 2007, Polymorphisms in the Vascular Endothelial Growth Factor Gene and Risk of Aging Macula Disorder: The Rotterdam Study, Invest. Ophthalmol. Vis. Sci., 48
- Green, 1996, Retina: growth and aging, Vol. 2, 676
- Hutchison, 1875, Symmetrical central choroidoretinal disease occurring in senile persons, R. Lond. Ophthal. Hosp. Rep, 8, 231
Cited by
Sorted by citations
Items 501–581 of 581
Jarmak, A. (2014) · OphthaTherapy Therapies in Ophthalmology
Pharmakologische Basis der Anti-VEGF Therapie
Schmetterer, L. F., & Garhöfer, G. (2012) · Spektrum der Augenheilkunde · doi:10.1007/s00717-012-0110-0
Atividade dos sistemas antioxidantes da microalga Minutocellus polymorphus frente exposição a cádmio
Decleva, D. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2012.tde-03102013-122749
Marin‐Castaño, M. E., & Pons, M. (2011) · Wiley eBooks · doi:10.1002/9783527635320.ch14
PAX6 in mammalian degenerative retina
Stanescu, D. (2010) · Research Publications (Maastricht University) · doi:10.26481/dis.20101213ds
Oxygen sensing mechanisms in retinal vascular development and disease
Lange, C. (2012) · UCL Discovery (University College London)
Serum omega-3 fatty acids are not associated with age-related macular degeneration
Brétillon, L., Simon, E., Acar, N., Berdeaux, O., Masson, E., Bron, A. M., & Creuzot-Garcher, C. P. (2012) · Expert Review of Ophthalmology · doi:10.1586/eop.11.74
Age-related macular degeneration: a case study
Kerr, E. (2010) · British Journal of Nursing · doi:10.12968/bjon.2010.19.11.48389
Function and pathology of the human retinal pigment epithelium
Booij, J. C. (2010) · UvA-DARE (University of Amsterdam)
Tuo, J. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.09.65
Brétillon, L., Acar, N., Bron, A. M., & Creuzot-Garcher, C. P. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.09.64
The role of retinoic acid related orphan receptor alpha in age-related macular degeneration
Hoang, H. (2015) · OpenBU (Boston University)
Ribeiro, S. D. V. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/grjv-me24
Adamiec-Mroczek, J., Zając-Pytrus, H. M., & Misiuk‐Hojło, M. (2014)
A Clinical Analysis of Age-Related Macular Degeneration in Qinghai Plateau
Zhu, A., & Li, L. (2016) · International Journal of Ophthalmic Pathology · doi:10.4172/2324-8599.1000179
“AMD is a highly complex and multifactorial disease with demographic, environmental, and genetic risk factors including aging, smoking, diet and race [1].”
BackgroundBehandlungsansätze bei trockener AMD
Yehoshua, Z., & Rosenfeld, P. J. (2011) · Springer eBooks · doi:10.1007/978-3-642-20870-6_17
Marincola, M. S. R. B. N. A. F. M. (2013) · doi:10.1201/b14790-11
Genetic and Genomic Approaches for Understanding Retinal Diseases
Howell, G. R., & John, S. W. M. (2009) · Neuromethods · doi:10.1007/978-1-60761-541-5_3
High-resolution retinal imaging with a compact adaptive optics ophthalmoscope
Kepiro, I. E. (2011) · Spiral (Imperial College London) · doi:10.25560/14297
Melekhin, Y. V., Khoroshikh, Y. I., & Krylova, A. A. (2014) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2014-1-166-171
Aflibercept for treatment of wet AMD in clinical practice
Moe, M. C. (2016) · NORA - Norwegian Open Research Archives
Gaybaryan, R. V., Epikhin, A. N., & Bondarenko, Y. F. (2017) · Ophthalmology in Russia · doi:10.18008/1816-5095-2017-1-78-83
Genetics and Pathology of Inflammatory Components on AMD
Li, X., Huang, L., Zhou, P., & Chan, C. (2017) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-4-431-56511-6_15
Self-citationLow-level night-time light therapy for age-related macular degeneration
Robinson, D. G. (2017) · ORCA Online Research @Cardiff (Cardiff University)
Iqbal, O. J., Brambl, W., & Ottman, A. (2015) · International Journal of Ophthalmology & Eye Science · doi:10.19070/2332-290x-1500025
“Several other etiologies have been discussed as well, such as the complement pathway, single nucleotide polymorphisms, macrophages, etc [3].”
BackgroundOther Ocular Disorders and the Immune Response
Nussenblatt, R. B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0667-3.00036-9
A Bioengineering Approach Towards Retina Regeneration
Mitrousis, N. (2018) · TSpace (University of Toronto)
Bilgic, A., & Sudhalkar, A. A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-231262
Avaliação funcional de fotorreceptores na degeneração macular relacionada à idade
Decleva, D. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.47.2019.tde-12112019-161223
Jovanović, S., Davidović, S., Miljković, A., Krstonošić, M. A., Sazdanić, D., & Mikulić, M. (2019) · Medicinski pregled · doi:10.2298/mpns1910291j
Bianchi, L. C. D. S. N., Vieira, L. T. Q., Isaac, D. L. C., & de Ávila, M. P. (2020) · Brazilian Journal of Development · doi:10.34117/bjdv6n9-062
Biomaterials Targeting AMD: Are We There Yet?Preprint
Lawless, R., Hidalgo‐Alvarez, V., & Haneef, A. S. (2020) · Preprints.org · doi:10.20944/preprints202012.0569.v1
“This causes the development of abnormal blood vessels from the underlying blood supply to the retina, the choroid, to push through the BM and retinal pigment epithelial cells (RPE)[13, 14] resulting in haemorrhaging and scar formation[12].”
BackgroundRaza, M. A., Riaz, A., Hamid, A. H., Khan, S. U., & Siddiqui, M. A. (2021) · Physica Scripta · doi:10.1088/1402-4896/abe6bf
ASSISTÊNCIA INTEGRAL: CONDUTAS PROFILÁTICAS E TERAPÊUTICAS EM GESTANTES COM ANEMIA FALCIFORME
Chaves, M. P., do Nascimento, N. R., Dornelas, M. A. D. M., de Godoy, A. A. R., & de Freitas, M. A. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000892
AUMENTO DE COROA CLÍNICA ESTÉTICA SUPERIOR
Dias, K. S. P. A., Silva, I. C. M., Rocha, C. R., & Freitas, H. E. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000896
ASTROCITOMA PILOCÍTICO CEREBELAR DE DESENVOLVIMENTO ATÍPICO: RELATO DE CASO
Ribeiro, L. M., Linhalis, B. S., Ferreira, K. D. M., de Souza, P. G. K., & Lee, S. Y. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000916
COLANGIOCARCINOMA AVANÇADO: UM RELATO DE CASO
Chixaro, J. D. O., de Oliveira, L. P., Colares, W. T. H. C., de Andrade, B. B., Santana, Y. M., Filho, K. P. D. O., & Cortez, M. V. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000917
Maia, M. R., & Celeste, L. E. N. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000911
O PAPEL DO ENFERMEIRO NA PREVENÇÃO DE INFECÇÃO NO SÍTIO CIRÚRGICO
Lauria, T. A. L. F., de Souza, M. T., de Oliveira, C. R. M., de Freitas, A. H., & Freitas, S. C. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000900
IMUNOTERAPIA NA DOENÇA DE HUNTINGTON: UMA REVISÃO SISTEMÁTIC
Martin, R. R. H., Gontijo, B. D. A. V., Guimarães, J. D. S., Toledo, R. G., Patricio, B. M. K., Verde, L. D. A. L. V., de Mesquita, H. L., Sousa, A. L., & Guimarães, L. C. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000903
Bianchi, L. C. D. S. N., Vieira, L. T. Q., Isaac, D. L. C., & de Ávila, M. P. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000904
LESÃO DE QUADRIL PREDOMINANTE EM TENISTAS: REVISÃO SISTEMÁTICA
Santos, J. V. D. S., do Nascimento, D. A., dos Santos, E. F., de Oliveira, É. M. P., da Silva, V. B., Bosnic, F., Falconi, C. A., & Doro, M. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000910
Camilo, L. D. L., da Silva, K. R., Galvão, C. A. L., Lazzareschi, L., Lima, S. C. D. C. R., da Silva, A., & Filoni, E. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000907
de Deus, M. H. A., Martins, J. M., Júnior, G. D., & Orsolin, P. C. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0000908
USO TERAPÊUTICO DA MACONHA EM PACIENTES COM GLAUCOMA: UMA REVISÃO
Pinto, J. T. T., Menegucci, G., Borini, P., & Pinto, F. T. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000901
da Silva, V. J., & de Alencar, J. L. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000906
EFETIVIDADE DA EMDR NO TRATAMENTO DO TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO: UMA REVISÃO INTEGRATIVA
Izotton, T. W., Báo, I., Zancanaro, M., & Sachser, R. M. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000902
ANÁLISE DOS IMPACTOS DA COVID-19 NO TRANSPLANTE HEPÁTICO
Feu, N. B., Bicalho, J. A. R., da Silva, E. R. T., Caprini, M. D., & Pacheco, M. P. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000914
NADPH Oxidase in Choroidal Neovascularization
Li, Q., Verma, A., Dinculescu, A., Lewin, A. S., & Hauswirth, W. W. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-606-7_14
Wang, Z., Liang, X., Wu, S., Zhang, J., Liu, Q., Yu, Y., Qi, B., Yang, X., Liu, L., Zhang, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1122941/v1
Mulki, L., Sweigard, J. H., & Connor, K. M. (2014) · Journal of Visualized Experiments · doi:10.3791/52130-v
Arshinoff, S. A. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718046008.793480995
Meleth, A. D., Raiji, V. R., Krishnadev, N., & Chew, E. Y. (2011) · Springer eBooks · doi:10.1007/978-3-642-20870-6_12
Cyclic stretch-induced VEGF expression is mediated by TGF-β in retinal pigment epithelial cellsPreprint
Liu, W., Chen, J., Wu, S., Zhang, J., Liu, Q., Liang, X., Wang, Z., Yu, Y., & Wang, J. (2019) · Research Square · doi:10.21203/rs.2.309/v1
“Also, TGF-β mediates collagen remodelling and scar contraction in the later stage of CNV, leading to scar tissue formation[42].”
BackgroundVitamin D and Age-Related Macular Degeneration
Jin, Y., Chen, X., Qin, J., & Yong, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815245-4.00009-0
Melatonin and Its By-Products on Age-Related Macular Degeneration
WATSON, R. R. (2011) · CRC Press eBooks · doi:10.1201/b11101-31
Emerging Concepts in Biomarker Discovery
Nussenblatt, R. B., & Marincola, F. M. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b14790-10
Rensing, L., & Rippe, V. (2013) · Springer eBooks · doi:10.1007/978-3-642-37733-4_13
Abordagens contemporâneas nas ciências da saúde
Silva, B. D. R., Mariano, L. M. F. D. H., de Oliveira, F. D. A. M., Netto, P. R. D. S., Parreira, J. R., de Almeida, W. B., dos Santos, D. M., Lima, V. D. S. B., Mendonça, A. M. B., Santos, L. H. S., et al. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed
Малачкова, Н. В., & Al-Jarrah, O. M. M. (2022) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2022-26(2)-16
“У свою чергу зацікавлюють запальні клітини, зокрема макрофаги, які були гістологічно репрезентовані в областях руйнування мембрани Бруха, атрофії пігментного епітелію сітківки та неоваскуляризації судинної оболонки [3].”
Liu, C., Ma, J., Mo, Y., & Duan, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1948852/v1
Liu, Y., Liu, H., Lu, P., & Dong, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2738381/v1
Usui, Y., Iwanishi, H., Sumiok, T., Ichikawa, K., Miyajima, M., Usui-Kusumoto, K., Reinach, P. S., Okada, Y., & Saika, S. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100232
RetractedSamra, Y. A., Kira, D., Rajpurohit, P., Mohamed, R., Owen, L. A., Shakoor, A., Kim, I. K., DeAngelis, M. M., Sheibani, N., Al‐Shabrawey, M., et al. (2022) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamol4ed.4.22.4
Gupta, A., Bansal, R., Sharma, A., & Kapil, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-7923-3_4
Yaşar, E., Gürlevik, U., Bilgeç, M. D., & Güneş, M. (2024) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.1420279
Yadav, D. S., Tivig, I. C., Savopol, T., & Moisescu, M. G. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03617-0
“AMD can be classified as atrophic damage to the RPE (dry-AMD) or neovascular disruption (wet-AMD) [7].”
BackgroundUozumi, H., Kawakami, S., Matsui, Y., Mori, S., & Sato, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-85158-0
Lin, L., Zheng, Q., Zong, Y., Dong, Y., & Gao, Q. (2025) · Thermal Science and Engineering Progress · doi:10.1016/j.tsep.2025.103480
RetractedImplants à base de PLGA pour la libération oculaire
Bode, C. (2019) · theses.fr (ABES) · doi:10.70675/db064711z80cez456aza9edzb4509e94b78b
Abdouh, M., Sebag, W., Abdouh, N., Goyeneche, A. A., & Burnier, M. N. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111034
Kumar, M., Trinh, M., Agrawal, R. V., & Nivison‐Smith, L. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.5.49
“13–16 Based on these observations, it is understood that there is a need to measure choroidal changes clinically in early stages as well.”
Lai, A. C., Issa, M., Ali, A., Pereira, A., Ali, A. A., Chhablani, J. K., & Yan, P. (2026) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264261457969
Kushwah, N., Liu, C., Bora, K., Meenakshi, M., Pavlovich, M. C., Fu, Z., Kamenecka, T. M., Sun, Y., Solt, L. A., & Chen, J. (2026) · Angiogenesis · doi:10.1007/s10456-026-10092-2
“Chemokines such as CX3CL1 engage with their respective receptors CX3CR1 on macrophages, facilitating their recruitment from circulation into the subretinal tissue and induce chronic inflammation via the secretion of pro-inflammatory mediators [ 22].”
Akmal, M. H., Mousavi, S. M., Lai, J., & Chiang, W. (2026) · Carbon · doi:10.1016/j.carbon.2026.122153
Metadata
- Authors
- Ding, X., Patel, M., & Chan, C.-C.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Chan, Chi-Chao
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 28
- Issue
- 1
- Pages
- 1-18
- ISSN
- 1350-9462 (ISSN-L)
- PMC
- PMC2715284
- OpenAlex
- W2084944408
- Semantic Scholar
- f9eb706832ee615a7771dad2f6ed351095c05219
- Cited by
- 582
- References
- 224
- Citations by year
- 2026: 5 · 2025: 21 · 2024: 17 · 2023: 16 · 2022: 24 · 2021: 43 · 2020: 20 · 2019: 34 · 2018: 34 · 2017: 36 · 2016: 33 · 2015: 39 · 2014: 39 · 2013: 44 · 2012: 53
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Progress in Retinal and Eye Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Eye Institute (Z01EY000222, Z01EY000418)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, molecular pathology, genetic susceptibility, complement factor H, CX3CR1, inflammation, apoptosis, cholesterol transport, angiogenesis, oxidative stress, retinal pigment epithelium, Bruch's membrane, choroidal capillaries, photoreceptor degeneration, animal models
- MeSH terms
- Animals, Disease Models, Animal, Humans, Macular Degeneration, Retina, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review